CD4 and non-Hodgkin lymphoma: In the case of hematological malignancies, patients with non-Hodgkin’s lymphoma (NHL) exhibit an increase in CD14+ HLA-DRlow-expressing monocytes, which possess immunosuppressive properties, along with elevated levels of CD4+ CD25+ Tregs [23,24].